Minor histocompatibility Ags (mHags) have been implicated in the pathogenesis of GVHD after allogeneic hematopoietic stem cell transplantation (HSCT). Uridine diphospho-glucuronosyltransferase 2B17 (UGT2B17) gene deletion may act as a mHag and its association with acute GVHD (aGVHD) has been described. We retrospectively studied the clinical impact of a UGT2B17 mismatch in a cohort of 1127 patients receiving a HSCT from an HLA-identical sibling donor. UGT2B17 mismatch was present in 69 cases (6.1%). Incidence of severe aGVHD was higher in the UGT2B17 mismatched pairs (22.7% vs 14.6%), but this difference was not statistically significant (P: 0.098). We did not detect differences in chronic GVHD, overall survival, relapse-free survival, transplant-related mortality or relapse. Nevertheless, when we analyzed only those patients receiving grafts from a male donor (616 cases), aGVHD was significantly higher in the UGT2B17 mismatched group (25.1% vs 12.8%; P: 0.005) and this association was confirmed by the multivariate analysis (P: 0.043; hazard ratio: 2.16, 95% confidence interval: 1.03-4.57). Overall survival was worse for patients mismatched for UGT2B17 (P: 0.005). We conclude that UGT2B17 mismatch has a negative clinical impact in allogeneic HSCT from HLA-identical sibling donors only when a male donor is used. These results should be confirmed by other studies.
INTRODUCTION UDP-glucuronosyltransferases (UGTs) are enzymes involved in the metabolism of steroid hormones and lipid-soluble drugs. Uridine diphospho-glucuronosyltransferase 2B17 (UGT2B17) is the most active enzyme in testosterone glucuronidation, acting as a detoxification enzyme, which catalyzes the glucuronidation of lipophilic compounds. The UGT2B17 gene is mapped to chromosome 4q13.
1 UGT2B17 is highly expressed in the liver and gastrointestinal tract, but also in extrahepatic steroid target tissues such as the prostate. 2 Interestingly, it has been described that men have higher UGT2B17 expression and activity than women. 3 The human UGT2B17 gene varies in copy number from zero to two per individual because of the presence of a polymorphism that consists of a 129-kb deletion. 4 The incidence of this gene deletion varies among populations on the basis of their ethnic background. 5, 6 In 2003, Murata et al. 7 described a novel minor histocompatibility Ag (mHag) encoded by UGT2B17, identifying a cytotoxic T-cell clone derived from a patient with GVHD that recognized the peptide AELLNIPFLY, derived from UGT2B17 and presented by HLA-A*29:02 and also by HLA-B*44:03. 8 New data revealed that CVATMIFMI, a different peptide derived from UGT2B17, is presented by the HLA allele HLA-A*02:06, frequently detected in Asiatic and Central American populations.
The Japanese group explored the impact of UGT2B17 on clinical outcome after allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated donors, 9 and although they did not find a significant association between UGT2B17 mismatch and the incidence of acute GVHD (aGVHD), they suggested that the use of a UGT2B17-positive donor was an independent risk factor for higher transplant-related mortality and lower survival after transplantation. In contrast, McCarroll et al. 10 analyzed three different cohorts of allogeneic HSCT from HLA-identical sibling donors and they found that the risk of aGVHD was greater when patient and donor were mismatched for UGT2B17 (donor UGT2B17 negative and recipient UGT2B17 positive) independent of the presence of the described HLA restriction alleles, suggesting that the gene deletion polymorphisms should be considered as potential targets for immune recognition after allogeneic transplantation.
The main objective of our study was to confirm the association of UGT2B17 mismatch with the incidence of aGVHD and the clinical outcome after allogeneic HSCT from an HLA-identical sibling donor.
PATIENTS AND METHODS Patients
We retrospectively studied a cohort of 1127 patients receiving an allogeneic HSCT from an HLA-identical sibling donor between 1991 and UGT2B17 genotyping DNA samples were obtained from patients' and donors' peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, GmbH, Hilden, Germany), according to the manufacturer's instructions and stored at − 80°C until use. UGT2B17 genotype was determined for both patients and donors by PCR with sequence-specific primers with allele-specific primers and conditions described by Spierings et al. 11 in a multiplex PCR reaction including primers specific for the HLA-DRB1 locus as an internal positive control. The amplified products were analyzed by electrophoresis in 3% agarose gel. Samples demonstrating the expected 353-bp band size were considered UGT2B17 positive, whereas the absence of this band in the presence of positive control amplification was considered as deletion of the gene (UGT2B17 negative). This PCR with sequence-specific primers method allows us to detect the UGT2B17 − / − genotype (deletion of both alleles) or the presence of at least one allele (UGT2B17 +/ − or +/+).
Statistical analysis
Homogeneity between UGT2B17 mismatched and non-mismatched donor-patient pairs was evaluated using the chi-square test for qualitative variables and Student's T-test for continuous variables.
A two-sided P-value of 0.05 or lower was considered to be statistically significant. Kaplan-Meier curves were derived to determine overall survival and disease-free survival, and were compared by means of the log-rank test. Cumulative incidence estimates were used to explore differences in aGVHD, transplant-related mortality and relapse incidence. aGVHD was defined by clinical criteria and late onset beyond day 100 was included if documented, mainly in patients receiving a non-myeloablative conditioning regimen. Death without signs of GVHD was considered as a competitive risk for aGVHD. The competing risk for relapse was death in CR.
Multivariate analysis was performed using the Cox regression model. All the variables with a P-value at or below 0.2 in the univariate analysis were included in the multivariate analysis.
RESULTS

UGT2B17 genotype
We detected the 'null' genotype (UGT2B17 − / − ) in 7.4% of the individuals studied. The UGT2B17 mismatch (defined by the presence of at least one UGT2B17 allele in the patient and the 'null' phenotype in the donor) was detected in 69 patient-donor pairs, representing 6.1% of the study cohort. The clinical characteristics of the UGT2B17 mismatched cohort and the non-mismatched patient-donor pairs are presented in Table 2 . All variables were comparable between the two groups.
Clinical outcome according to the UGT2B17 mismatch The cumulative incidence of grades II-IV aGVHD was comparable between the patients receiving a UGT2B17 mismatched graft and those without this mismatch (35.3% vs 34.4%; P: 0.854). When considering only severe (grades III-IV) aGVHD, we detected a trend toward an increased incidence of this complication in the presence of a UGT2B17 mismatch (22.7% vs 14.6%; P: 0.098) (Figure 1a ), but the multivariate analysis failed to detect statistical significance to consider the UGT2B17 mismatch as an independent risk factor for grades III-IV aGVHD (P: 0.336).
Similarly, we did not detect statistical differences between the UGT2B17 mismatched or matched pairs in the incidence of chronic GVHD (49.1% vs 45.1%; P: 0.573), relapse incidence (22.2% vs 25.1% at 2 years; P: 0.986) or transplant-related mortality (19.9% vs 19.7% at 1 year and 23.7% vs 22.3% at 2 years; P: 0.654). As expected, given the above-mentioned results, there were no differences in overall survival (median 8.2 years for patients with UGT2B17 mismatch vs 7.4 years for those without mismatch; P: 0.779) (Figure 1c ) or disease-free survival (median 2.3 vs 2.5 years; P: 0.781).
We also explored whether the UGT2B17 genotype of the donor conditioned the clinical outcome after allogeneic transplant from HLA-identical sibling donors as Terakura et al. suggested. However, we failed to find any clinical correlation with the presence of at least one UGT2B17 allele in the donor.
UGT2B17 mismatch and gender of the donor As has been described, the combination of female donor and male recipient is associated with an increased risk of aGVHD and worse survival, mainly due to the presence of several Y-chromosome codified mHags (H-Y mismatches). As the effect of these mismatches seem to be immunodominant after allogeneic HSCT, we attempted to establish whether or not the UGT2B17 mismatch had any impact on clinical outcome in the absence of such mismatches. Thus, from the entire cohort we selected 828 patient-donor pairs without the H-Y mismatch. From these pairs, 53 cases (6.4%) were UGT2B17 mismatched and we detected a statistically significant increase in incidence of grades III-IV aGVHD in these patients (25.1% vs 12.8%; P: 0.031) and a trend toward a worse overall survival (median 3.1 vs 14.6 years; P: 0.107).
However, we found that this worse clinical outcome was not conditioned by the H-Y mismatch but by the use of a male donor, independently of the gender of the recipient. When analyzing the 616 transplants performed from a male sibling donor, we detected a statistically significant increase in aGVHD grades III-IV (29.9% vs 12.8%; P: 0.005) (Figure 1b) . The multivariate analysis in this group of patients identified the UGT2B17 mismatch as an independent risk factor for developing grades III-IV aGVHD (P: 0.043; hazard ratio (HR): 2.16, 95% confidence interval (CI): 1.03-4.57). This increase in severe aGVHD was associated with a trend toward an increased transplant-related mortality in univariate analysis (24.8% vs 17.3% at 1 year, 30.7% vs 20% at 2 years and 37.9 vs 22.1% at 5 years after transplant; P: 0.082). No significant differences were found in the incidence of either disease relapse (P: 0.466) or chronic GVHD (41.9% vs 40%; P: 0.835). In this cohort of patients, Abbreviations: BM = bone marrow; PB = peripheral blood; RIC = reduced intensity conditioning regimen.
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overall survival was significantly worse in the presence of a UGT2B17 mismatch (median 1.1 years vs not reached; P: 0.005) (Figure 1d ). Disease-free survival was also statistically inferior in the UGT2B17 mismatched transplants (median 0.8 vs 2.1 years; P: 0.031). However, this deleterious impact on overall or diseasefree survival was not confirmed in the multivariate analysis. Tables reflecting the univariate and multivariate analyses in the different analyzed cohorts are available as Supplementary Material.
DISCUSSION
mHags are MHC-associated peptides, which trigger T-cell responses that mediate GVHD and GVL effect.
12,13
The majority of mHags result from diallelic single-nucleotide polymorphisms that generate amino-acid sequence differences or variability in protein expression levels. In contrast, the UGT2B17 immunogenicity results from differential expression in donor and recipient cells as a consequence of a homozygous deletion of the UGT2B17 gene. Moreover, as UGT2B17 is a large protein (530 amino acids), it has been hypothesized that it may give rise to multiple antigenic epitopes, increasing the potential immunogenicity of the UGT2B17 mismatch in an allogeneic setting.
The potential immunogenicity of the UGT2B17 mismatch has been a focus of interest in the context of allogeneic HSCT. In 2005, Terakura et al. 9 described the clinical outcome of 435 patients receiving an allogeneic HSCT from HLA-identical unrelated donors, Abbreviations: BM = bone marrow; MDS = myelodysplastic syndrome; PB = peripheral blood; UGT2B17 = uridine diphospho-glucuronosyltransferase 2B17. Advanced disease was considered for patients with acute leukemia beyond the first CR, CML beyond the first chronic phase, and progressive disease for patients with MDS, multiple myeloma or lymphoma. Patient/donor CMV + indicates positive IgG CMV serology. and they failed to detect significant association between UGT2B17 mismatch and the incidence of aGVHD, chronic GVHD, relapse or survival. Nevertheless, they found that the use of a UGT2B17-positive donor was an independent risk factor for higher transplant-related mortality and lower overall survival. In contrast, McCarroll et al. 10 analyzed three HSCT cohorts (424, 336 and 595 HLA-identical sibling donor-recipient pairs), and they found that risk of aGVHD was greater in the presence of a UGT2B17 mismatch considered as an insertion-deletion polymorphism, without considering HLA restriction. Although the exact number of mismatched pairs was not reported, given an expected incidence of 5-6% the analysis was likely carried out on approximately 20-35 mismatched pairs in each cohort. Analysis of smaller cohorts of patient-donor pairs by other groups have detected a similar association. 14, 15 More recently, Spierings et al. 16 carried out a multicenter analysis exploring the clinical impact of several mHags on GVHD in a cohort of 639 patients receiving an allogeneic HSCT from an HLA-identical related donor and 210 from an unrelated donor. Although they tried to explore the role of mismatches for the mHags UGT2B17/A29 and UGT2B17/B44, the analysis could not be addressed because of the low numbers of relevant mismatched pairs, and they did not assess the impact on clinical outcome of the UGT2B17 mismatch regardless of the MHC restriction.
In our experience, the UGT2B17 mismatch, defined as the presence of homozygous UGT2B17 deletion in the donor but not in the patient, shows no significant association with any of the clinical variables analyzed. Similarly, we did not find any clinical differences when the donor was UGT2B17+ in contrast with Terakura et al. However, we found that the UGT2B17 mismatch was an independent risk factor for severe aGVHD only when a male donor was used.
This observation may be related to several factors. The use of a male donor excludes the presence of the H-Y mismatches conditioned by the combination male recipient-female donor. As the presence of many immunogenic peptides derived from the Y-chromosome may be immunodominant, the clinical relevance of the autosomal mHags could be impaired in the presence of H-Y mismatches.
Moreover, the observation that the effect of the UGT2B17 mismatch is even more evident when considering only male donors may suggest that the H-Y immune dominance effect could extend to female donors having their T-cell repertoire narrowed by H-Y sensitization. In this context, the clinical relevance of other null allele disparities remains to be explored.
Gallagher et al. 3 showed that there are sex differences in UGT2B expression and activity, with men exhibiting a higher level of expression of UGT2B17 and a higher level of glucuronidation activity than women. Moreover, the condition of UGT2B17 mismatch by itself assumes the presence of at least one UGT2B17 allele in the recipient. As UGT2B17 is involved in glucuronation activity in liver microsomes and it has been described that cyclosporine A metabolism may be partially mediated by glucuronation by members of the UGT2B family, one hypothesis to consider is that the metabolism of cyclosporine A may be faster in recipients expressing UGT2B17, increasing the risk of GVHD in the presence of immunogenic mismatches. Unfortunately, gel analysis of PCR products is not able to distinguish UGT2B17 heterozygous +/ − from homozygous +/+ and this technical limitation does not allow us to determine if the allelic burden is relevant in this context.
Owing to the low frequency of the UGT2B17 mismatch, only studies analyzing large cohorts of homogeneous HSCT from HLA-identical sibling donors can be helpful in clarifying its clinical relevance. Our results seem to contradict previous reports and the UGT2B17 mismatch has only a marginal effect on aGVHD, when a male donor is used, however, these results should be considered as a preliminary and need to be confirmed by other studies.
